Obinutuzumab: A Review of Its Use in Patients with Chronic Lymphocytic Leukaemia

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

(2014) G. Cartron et al.   BLOOD

Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity

(2014) S. Herter et al.   JOURNAL OF IMMUNOLOGY

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Indirect Treatment Comparisons Of Obinutuzumab (Ga101) Plus Chlorambucil (Clb) Versus Bendamustine And Versus Ofatumumab Plus Clb In Patients With Chronic Lymphocytic Leukemia

(2014) T Waterboer et al.   VALUE IN HEALTH

Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties

(2013) S. Rafiq et al.   JOURNAL OF IMMUNOLOGY

Monoclonal antibodies targeting CD20

(2013) Chien-Hsing Chang et al.   mAbs

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

(2013) Christian Klein et al.   mAbs

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

(2013) S. Herter et al.   MOLECULAR CANCER THERAPEUTICS

The Potential Cost-Effectiveness of Obinutuzumab (Ga101) in Combination with Chlorambucil in Chronic Lymphocytic Leukemia

(2013) S. Walzer et al.   VALUE IN HEALTH

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

(2012) G. Salles et al.   BLOOD

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

(2012) L. H. Sehn et al.   BLOOD

Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2011) B. Eichhorst et al.   ANNALS OF ONCOLOGY

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients

(2008) Constantine S. Tam et al.   BRITISH JOURNAL OF HAEMATOLOGY